Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1993 1
1994 3
1995 1
1996 2
1997 4
1998 1
2000 4
2001 2
2002 1
2003 4
2004 1
2005 2
2006 1
2007 1
2008 1
2011 5
2012 5
2013 3
2014 3
2015 4
2016 3
2017 1
2018 3
2019 3
2020 3
2021 2
2022 3
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
An update on the central nervous system manifestations of neurofibromatosis type 1.
Nix JS, Blakeley J, Rodriguez FJ. Nix JS, et al. Acta Neuropathol. 2020 Apr;139(4):625-641. doi: 10.1007/s00401-019-02002-2. Epub 2019 Apr 8. Acta Neuropathol. 2020. PMID: 30963251 Free PMC article. Review.
A subset of low-grade astrocytomas in these patients remain difficult to classify using standard criteria, and occasionally demonstrate morphologic features resembling subependymal giant cell astrocytomas that afflict patients with tuberous sclerosis complex ("SEGA-like as …
A subset of low-grade astrocytomas in these patients remain difficult to classify using standard criteria, and occasionally demonstrate morp …
Rare glial tumors.
Soffietti R, Rudà R, Reardon D. Soffietti R, et al. Handb Clin Neurol. 2016;134:399-415. doi: 10.1016/B978-0-12-802997-8.00024-4. Handb Clin Neurol. 2016. PMID: 26948368 Review.
This chapter describes the epidemiology, pathology, molecular characteristics, clinical and neuroimaging features, treatment, outcome, and prognostic factors of the rare glial tumors. This category includes subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma …
This chapter describes the epidemiology, pathology, molecular characteristics, clinical and neuroimaging features, treatment, outcome, and p …
Neurological malignancies in neurofibromatosis type 1.
Eoli M, Saletti V, Finocchiaro G. Eoli M, et al. Curr Opin Oncol. 2019 Nov;31(6):554-561. doi: 10.1097/CCO.0000000000000576. Curr Opin Oncol. 2019. PMID: 31436563 Review.
RECENT FINDINGS: The association between the risk of developing optic pathway glioma and specific germiline NF1 mutations is still debated and further studies are needed with large, new cohorts of patients. ...Some neoplasms, very rare in general population, such as sub …
RECENT FINDINGS: The association between the risk of developing optic pathway glioma and specific germiline NF1 mutations is still de …
Ependymomas.
Chamberlain MC. Chamberlain MC. Curr Neurol Neurosci Rep. 2003 May;3(3):193-9. doi: 10.1007/s11910-003-0078-x. Curr Neurol Neurosci Rep. 2003. PMID: 12691623 Review.
Imaging characteristics of 4th ventricle subependymoma.
Haider AS, El Ahmadieh TY, Haider M, Hatanpaa KJ, Pinho MC, Mickey BE, Sawaya R, Fuller GN, Schomer DF, Gule-Monroe M. Haider AS, et al. Neuroradiology. 2022 Sep;64(9):1795-1800. doi: 10.1007/s00234-022-02944-7. Epub 2022 Apr 15. Neuroradiology. 2022. PMID: 35426054 Free PMC article. Review.
MRI of intracranial intraventricular lesions.
Muly S, Liu S, Lee R, Nicolaou S, Rojas R, Khosa F. Muly S, et al. Clin Imaging. 2018 Nov-Dec;52:226-239. doi: 10.1016/j.clinimag.2018.07.021. Epub 2018 Aug 1. Clin Imaging. 2018. PMID: 30138862 Review.
Imaging and pertinent clinical features of the following intraventricular neoplasms are reviewed: ependymoma, subependymoma, central neurocytoma, subependymal giant cell tumor, choroid plexus tumors, medulloblastoma, meningioma, chordoid glioma, rosette-forming glio …
Imaging and pertinent clinical features of the following intraventricular neoplasms are reviewed: ependymoma, subependymoma, central neurocy …
Characterization of gliomas: from morphology to molecules.
Ferris SP, Hofmann JW, Solomon DA, Perry A. Ferris SP, et al. Virchows Arch. 2017 Aug;471(2):257-269. doi: 10.1007/s00428-017-2181-4. Epub 2017 Jul 4. Virchows Arch. 2017. PMID: 28674742 Review.
The entities reviewed within include diffuse gliomas (astrocytoma, oligodendroglioma, glioblastoma), as well as circumscribed and low-grade gliomas (angiocentric glioma, pilocytic astrocytoma, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma, pilom …
The entities reviewed within include diffuse gliomas (astrocytoma, oligodendroglioma, glioblastoma), as well as circumscribed and low-grade …
Biology and management of ependymomas.
Wu J, Armstrong TS, Gilbert MR. Wu J, et al. Neuro Oncol. 2016 Jul;18(7):902-13. doi: 10.1093/neuonc/now016. Epub 2016 Mar 28. Neuro Oncol. 2016. PMID: 27022130 Free PMC article. Review.
Molecular profiling of gliomas: potential therapeutic implications.
Alentorn A, Duran-Peña A, Pingle SC, Piccioni DE, Idbaih A, Kesari S. Alentorn A, et al. Expert Rev Anticancer Ther. 2015;15(8):955-62. doi: 10.1586/14737140.2015.1062368. Epub 2015 Jun 28. Expert Rev Anticancer Ther. 2015. PMID: 26118895 Review.
Among many molecular abnormalities, BRAF mutation and mTOR activation in pilocytic astrocytomas and subependymal giant cell astrocytomas are actionable targets sensitive to vemurafenib and everolimus, respectively. ...
Among many molecular abnormalities, BRAF mutation and mTOR activation in pilocytic astrocytomas and subependymal giant cell astrocyto …
64 results